Novartis lung cancer drug gets priority U.S. review

Novartis has won fast-track U.S. regulatory review for capmatinib (INC280) in a hard-to-treat form of lung cancer, the Swiss drugmaker said on Tuesday.

Capmatinib is a MET inhibitor being evaluated as a treatment for first-line and previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer.

"If approved, capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis," Novartis said in a statement.

Source:https://health.economictimes.indiatimes.com/news/pharma/novartis-lung-cancer-drug-gets-priority-u-s-review/74077997



Comments

Post a Comment

Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product ramucirumab (Cyramza). The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. The CHMP adopted a new indication as follows: “Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib”. For information, the full indications for Cyramza will be as follows : Gastric cancer Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatm
Read more

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

The goal of Fred Hutch Global Oncology, says Dr. Hootie Warren, its newly named head, is "to figure out how we can adapt the incredibly exciting work that’s done here so that it can benefit people all around the world.” Photo by Robert Hood / Fred Hutch News Service Immunotherapy researcher and oncologist  Dr. Edus H. Warren  works on the front lines of a revolution. In his 24 years at Fred Hutchinson Cancer Research Center, Warren, who goes by the nickname “Hootie,” has contributed to jaw-dropping discoveries in harnessing the immune system to fight cancer. Today  immunotherapy  is considered the most exciting advance in decades, joining surgery, radiation therapy and chemotherapy as a fourth pillar of cancer care. Now, as the new head of  Fred Hutch Global Oncology , he is set to lead a revolution that could be just as transformative: improving cancer care in sub-Saharan Africa and other regions that do not always have access to even the first three pillars. Fred
Read more

Merck announces positive event-free survival data from phase 3 KEYNOTE-522 study of Keytruda to treat triple-negative breast cancer

Merck announced positive event-free survival (EFS) data from the pivotal neoadjuvant/adjuvant phase 3 study KEYNOTE-522. The trial investigated neoadjuvant Keytruda, Merck’s anti-PD-1 therapy, plus chemotherapy followed by adjuvant Keytruda as monotherapy (the Keytruda regimen) compared with neoadjuvant chemotherapy followed by adjuvant placebo (the chemotherapy-placebo regimen) in patients with high-risk early-stage triple-negative breast cancer (TNBC). This is the first time an anti-PD-1/L1 therapy has demonstrated a statistically significant EFS result as combined neoadjuvant and adjuvant therapy for these patients. These results are being presented today during a European Society for Medical Oncology (ESMO) Virtual Plenary. After a median follow-up of 39 months, the Keytruda regimen reduced the risk of EFS events by 37% (HR=0.63 [95% CI, 0.48-0.82]; p=0.00031) versus the chemotherapy-placebo regimen – a statistically significant and clinically meaningful EFS result. EFS was defined
Read more